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Abstract Human pluripotent stem cells (hPSCs) present a potentially unlimited
source of specialized cell types for regenerative medicine. Over the last few years
there has been rapid progress in realizing this potential by developing protocols to
generate disease-relevant cell types in vitro on demand. The approach was parti-
cularly successful for the nervous system, where the field is at the verge of human
translation for several indications, including the treatment of eye disorders,
Parkinson’s disease and spinal cord injury. More recently, there has also been
success in deriving anterior pituitary lineages from both mouse and human pluri-
potent stem cells. In vitro-derived pituitary hormone-producing cell types present an
attractive source for repair in patients with hypopituitarism. However, several
hurdles remain towards realizing this goal. In particular, there is a need to further
improve the efficiency and precision with which specific hormone-producing line-
ages can be derived. Furthermore, it will be important to assess the potential of both
ectopic and orthotopic transplantation strategies to achieve meaningful hormone
replacement. The ultimate challenge will be repair that moves beyond hormone
replacement towards the full functional integration of the grafted cells into the
complex regulatory endocrine network controlled by the human pituitary gland.
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Derivation of Human Neural Cell Types for Regenerative
Medicine
The isolation of human embryonic stem cells (ESCs; Thomson et al. 1998) and the
remarkable feat of reprogramming somatic cells back to pluripotency via induced
pluripotent stem cell (iPSC) technology (Takahashi et al. 2007; Takahashi and
Yamanaka 2006; Yu et al. 2007) have set the stage for a new era of regenerative
medicine. Human pluripotent stem cells (hPSCs), a term comprising both human
ESCs and iPSCs, are characterized by their potential to differentiate into any cell
lineage of the body. For many years, the main challenge in the field has been to
capture the broad differentiation potential of hPSCs towards specific cell lineages
relevant to modeling and treating human disease. However, there has been consi-
derable progress recently in establishing differentiation protocol for many key
lineages such as endoderm-derived insulin-producing pancreatic cells (Pagliuca
et al. 2014; Rezania et al. 2014) for the treatment of diabetes or mesoderm-derived
cardiac cells for heart repair (Chong et al. 2014). Some of the most dramatic
successes, however, have involved ectoderm-derived lineages, in particular retinal
and CNS lineages (for review see Tabar and Studer 2014)). In fact, the very first
attempts at translating ESC technology towards the treatment of human patients
was based on the use of oligodendrocyte precursor-like cells in patients with spinal
cord injury (SCI: Alper 2009; Priest et al. 2015). However, SCI patients represent a
challenging target for cell therapy, as the primary defect is a problem of connec-
tivity between the brain and spinal cord rather than the loss of a specific cell type.
Currently, the most widely pursued clinical target is the transplantation of hPSC-
derived retinal pigment epithelial cells (RPEs) in patients with macular degenera-
tion. There are nearly a dozen different RPE-based clinical trials either ongoing or
in the planning phase (Kimbrel and Lanza 2015). Initial results using hESC-derived
RPEs suggest that the approach can be translated safely into humans (Schwartz
et al. 2015).
Beyond eye disorders, there has been particular interest in developing cell-based
therapies for the treatment of various neurodegenerative disorders. In the case of
Parkinson’s disease (PD), several studies demonstrated excellent in vivo survival of
hPSC-derived midbrain dopamine (mDA) neurons in mouse, rat and non-human
primate hosts (Kirkeby et al. 2012; Kriks et al. 2011). The transplantation of mDA
neurons represents an example of replacing a highly specific neuronal subtype and a
strategy that is thought to involve functional integration of the grafted cells into the
existing neuronal networks. Indeed, a recent study from our group used opto-
genetics to demonstrate that functional rescue in the PD host animals depended
on the continued neuronal activity of the grafted hESC-derived mDA neurons, and
“switching-off” the graft led to a reversal of functional benefit within minutes
(Steinbeck et al. 2015). The ability to derive mDA neurons from hESCs and hiPSCs
and the promising pre-clinical data have set the stage for ongoing translational
efforts towards testing this approach in human PD patients. Clinical trials are being
planned in the US, Japan and Sweden, which have led to the formation of G-Force
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PD, a global effort to coordinate hPSC-based cell therapy efforts in PD (Barker
et al. 2015). Another neurodegenerative disease being targeted is Huntington’s
disease where several protocols have been published to generate authentic, striatal
medium spiny neurons and where there is some initial evidence of efficacy in
preclinical models (Arber et al. 2015; Delli Carri et al. 2013; Ma et al. 2012).
Finally, several promising strategies are under development using glial cells. These
include the transplantation of hPSC-derived oligodendrocytes in genetic models of
white matter loss (Wang et al. 2013) and the remyelination of the brain following
radiation-induced brain damage (Piao et al. 2015), a common and serious problem
in cancer patients subjected to cranial irradiation (Greene-Schloesser et al. 2012;
Schatz et al. 2000).
With our increasing ability to generate potentially any neural lineage on demand,
the main challenge in the field has moved beyond making a specific cell type
towards translation and therapy development in regenerative medicine. While the
initial therapeutic targets for cell therapy are focused on replacing highly defined
populations of cells such as RPEs or mDA neurons, it may be necessary in future
studies to replace multiple cell types in combination to achieve meaningful rescue
in a broader range of human disorders. A particular challenge for neuronal cell
therapies is the importance of developing pre-clinical and ultimately clinical evi-
dence that in vitro-derived cells can integrate into the complex circuitry of the
human brain.
Derivation and Application of Human Pituitary Lineages
Replacing endocrine cells is conceptually more straightforward than replacing CNS
neurons because there is no need to re-establish a complex synaptic circuitry to
achieve improved function. However, the pituitary gland is also highly complex
and acts as the master regulator of endocrine function, controlling a diverse range of
responses in the body including stress control, growth and sexual function. Such
complexity makes any treatment of hypopituitarism - the loss of pituitary function –
challenging, as many hormones need to be replaced in a coordinated manner. In the
context of cell therapy, this requires the ability to generate multiple hormone-
producing cells at scale and on demand. To date, the main focus of hPSC-based
approaches for treating endocrine disorders has been on the treatment of type I
diabetes (Bruin et al. 2015). One key rationale for proposing a cell-based approach
in diabetes is successful derivation of functional islet cells from hPSCs (Pagliuca
et al. 2014; Rezania et al. 2014) and the expectation that grafted pancreatic β-cells
will establish a feedback loop sensing glucose and adjusting insulin levels conti-
nuously throughout the day, something that is difficult to achieve by insulin injec-
tions. Furthermore, it appears likely that regulatory control can be achieved with
cells that are not placed orthotopically into the pancreas but injected into a
surgically more accessible tissue with high vascularity, such as the spleen or liver
(Bruin et al. 2015). In contrast, orthotopic placement may be more critical for
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pituitary cells that respond to rapid and short acting signals from the hypothalamus.
The challenge of recreating anterior pituitary lineage diversity in vitro was first
tackled using mouse ESC cells. In a seminal study by the Sasai lab (Suga
et al. 2011), a differentiation protocol was presented that allowed the derivation
of mouse pituitary lineages via a serum-free embryoid body (SFEBq) culture step.
SFEBq conditions were initially developed to generate forebrain lineages from
mouse (Watanabe et al. 2005) and subsequently from human ESCs (Eiraku
et al. 2008). In contrast to the forebrain, which is derived from the CNS, the anterior
pituitary gland is derived from the oral ectoderm, which is part of the cranial
placode lineages during development. To direct cell lineage towards oral ectoderm,
Suga et al. (2011) showed that BMP4 exposure could trigger the induction of
PITX2, an oral ectoderm marker, at the periphery of the differentiating SFEBs.
Subsequent exposure to agonists of sonic hedgehog (SHH) signaling triggered
expression of LHX3, which is a definitive anterior pituitary lineage marker. One
remarkable feature during the induction process is the morphogenetic movements
of the oral ectoderm that mimic the formation of Rathke’s pouch, an invagination of
the oral ectoderm occurring during development that results in anterior pituitary
gland formation. However, the overall efficiency of generating Pitx2+ oral ecto-
derm cells was low and most cells in the SFEBq cultures retained a neural identity.
Approximately 1–7% of the non-neural cells expressed specific hormones, a
number that was dependent on further modulation of WNT activation for induction
of growth hormone- (GH) or prolactin (PRL)-producing cells or inhibition of Notch
signaling for obtaining ACTH+ cells (Suga et al. 2011). For the in vitro-derived
ACTH+ cells, Suga et al. (2011) demonstrated CRH-dependent hormone secretion
in vitro. Furthermore, transplanted cells were able to survive in vivo in an animal
with surgically induced hypopituitarism, and they extended the life span of those
animals, presumably by partially restoring their stress response. Some of the key
questions raised by the Suga et al. study include whether the same technology can
be applied for human ESC and iPSCs, whether the overall yield of anterior pituitary
placode and hormone-producing cells can be improved and whether the 3D culture
step, allowing the interaction of oral ectoderm-like and hypothalamic tissue, is
critical for the efficient induction of anterior pituitary lineage cells.
Some initial answers to these questions came from an independent effort in our
laboratories aimed at inducing cranial placode lineages from hPSCs (Dincer
et al. 2013). Similar to the SFEBq technology, the human placode induction
strategy was based on a protocol, dual-SMAD inhibition (Chambers et al. 2009),
that was initially developed for inducing forebrain fates. Under dual-SMAD inhi-
bition conditions, a monolayer of human ESCs or iPSCs can be converted at nearly
100% efficiency into PAX6+ anterior neuroectoderm within about 10 days of
differentiation (Chambers et al. 2009). Dual-SMAD inhibition involves concomi-
tant exposure of hPSCs to inhibitors of BMP signaling (either Noggin or the ALK2/
3 inhibitor LDN193189) and inhibitors of TGFβ, Activin and Nodal signaling
(commonly via the small molecule compound SB431542). In Dincer
et al. (2013), we showed that the key difference between CNS versus placode
induction was the inhibition versus activation of BMP signaling. In contrast to
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the induction of CNS lineage under conditions of dual-SMAD inhibition, placode
induction requires the timed removal of the BMP inhibitor at 48 h after neural
induction, allowing endogenous BMP signaling to rebound. Under these default
placode induction conditions, the majority of the hPSC-derived cells expressed
PAX3, suggestive of trigeminal placode fate (Dincer et al. 2013). However, upon
activation of SHH signaling, there was a marked increase in oral ectoderm markers
such as PITX1 and SIX6. Further differentiation of these pituitary placode pre-
cursors was shown to yield various hormone-expressing cells, including ACTH+,
FSH+ and GH+ lineages with clear evidence of in vitro hormone release. Finally,
our study demonstrated that subcutaneous injection of hPSC-derived pituitary pre-
cursors into nude rats yielded measurable levels of ACTH and GH secretion in vivo.
The findings of Dincer et al. suggested that the robust induction of human pituitary
hormone-expressing cells did not require a 3D culture step. However, the overall
efficiency of pituitary placode induction remained suboptimal. Furthermore, the
media conditions during differentiation included components such as knockout
serum-replacement (KSR) that are known to introduce batch-to-batch variability
into the differentiation process. Furthermore, the study did not attempt to enrich for
specific hormone lineages that may be required to develop better tailored therapies
for each individual patient. A first step towards optimizing cranial placode induc-
tion in the absence of KSR was achieved by another study that carefully optimized
the timing of BMP4 application (Leung et al. 2013). The results indicated that early
exposure to BMP4 could increase overall cranial placode yield whereas the subse-
quent inhibition versus activation of BMP at later stages of differentiation could
modulate the regional identity of hESC-derived placodal cells from PAX6+ anterior
to PAX3+ posterior placode (Leung et al. 2013). Finally, the study confirmed that
activation of SHH signaling increased the expression of oral ectoderm markers
including PITX1 and PITX2.
More recently, members of the Sasai lab presented a study that adapted their 3D
approach to human cells (Ozone et al. 2016). The study was based on a modified
SFEBq culture system triggering differentiation in the presence of KSR, SHH
agonist and BMP4 to yield 3D structures composed of hypothalamic cells in the
center of the 3D aggregates and oral ectoderm cells at the periphery. In a proportion
of those structures, the authors again observed the spontaneous formation of
Rathke’s pouch-like structures similar to their original data in mouse ESCs, though
at a lower frequency. While the overall induction efficiency of definitive pituitary
lineages remained low, the authors were able to demonstrate both basal and
CRH-induced release of ACTH in vitro that was shown to be suppressed by
hydrocortisone treatment. Similarly, induction of GH could be modulated both
positively and negatively by exposure to GHRH or somatostatin, respectively.
Finally, subcutaneous injection of the 3D aggregates into mice with surgical
hypophysectomy showed evidence of in vivo ACTH production that was respon-
sive to CRH treatment. The transplanted cells also triggered significant, albeit very
low, levels of corticosterone production and led to improved body weight and
survival as compared to sham-grafted animals in hypophysectomized hosts.
Some of the key remaining challenges include further improving the efficiency and
reliability of pituitary lineage differentiation with a greater percentage of hormone-
producing cells.
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Perspectives and Challenges on the Road to Translation
The adenohypophysis (pituitary) is a remarkable endocrine organ that orchestrates
the function of multiple targets via secretion of a set of regulatory hormones in
charge of vital functions such as development, growth, puberty, reproduction,
lactation and, crucially, response to stress. It receives regulatory endocrine input
from the adjacent hypothalamus through a portal circulation system and commu-
nicates with the rest of the organism via an extensive network of vessels. Multi-
tiered feedback is integrated by this master gland, leading to hormonal and meta-
bolic homeostasis (Tabar 2011). The role of regenerative approaches to the adeno-
hypophysis has received very little attention despite the prevalence of pituitary
disorders and the large number of patients requiring pituitary hormone replacement
due to traumatic brain injury, genetic, sporadic or iatrogenic disease. Several
syndromes of pituitary deficiencies are recognized in humans as the result of
mutations of early transcription factors or cell cycle regulator proteins (Melmed
2011). One of the prevalent causes of pituitary deficiency is post-treatment pituitary
and hypothalamic damage. Specifically, and of interest to us, is a group of patients
who suffer from hypopituitarism as a consequence of brain radiation for a variety of
disorders, including hematological malignancies, head and neck cancers, brain
tumors and sellar lesions (Appelman-Dijkstra et al. 2011). In fact, growing interest
in cancer survivorship has identified hypopituitarism as a major contributor to poor
quality of life indices (Darzy 2009). The clinical consequences are extensive and
include fatigue, poor concentration, decreased memory and general cognitive
abilities as well as significantly reduced well-being. In children these consequences
are compounded by more serious learning difficulties and growth and skeletal
problems, as well as a major impact on puberty and sexual function (Chemaitilly
and Sklar 2010). Radiation damage to the hypothalamus and pituitary regions is
progressive and irreversible. Current treatment consists of life-long multiple hor-
mone replacement therapies, a suboptimal solution since static delivery of these
molecules is a poor substitute for normal pituitary gland features such as the
dynamic secretion of hormones in response to circadian patterns, feedback mech-
anisms or stressful conditions. In addition, treatment can be prohibitively expen-
sive, with costs of growth hormone replacement alone exceeding $20,000 per year.
One of the key challenges to restorative strategies, regardless of the etiology of
hypopituitarism, involves decisions regarding orthotopic or ectopic graft implanta-
tion. Grafts of pituitary tissue or primary cell suspensions from human fetal or
rodent sources have been performed extensively using ectopic (Fu and Vankelecom
2012) or more or less orthotopic placement in the pituitary (Falconi and Rossi
1964), hypothalamus (Tulipan et al. 1985) or in the third ventricle (Vuillez
et al. 1989). Overall, pituitary tissue or cells survive very well with the exception
of conditions of immunological mismatch. A major concern with ectopic (i.e.,
subcutaneous or kidney) placement is the absence of hypothalamic control. The
adenohypophysis is connected to the hypothalamus by a portal vein system that
allows the immediate delivery of hypothalamic factors, thus bypassing the systemic
circulation. Data from transplants in the hypothalamus, third ventricle or the
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hypophysis sites suggest that pituitary grafts demonstrate improved function and
response to feedback when they are in immediate contact with the hypothalamus
(Harris and Jacobsohn 1952; Maxwell et al. 1998). Some of the most successful
results have been obtained upon transplantation in hypophysectomized female rats
at the level of the median eminence, with good outcomes including restoration of
estrus cycles, ability to conceive and lactate pups, adequate growth hormone and
ACTH levels, as well as near normalization of body size in comparison to normal
controls (Harris and Jacobsohn 1952). Data from transplantation of mouse
ESC-derived pituitary cells (injected in the renal capsule) suggested statistically
significant elevation of basal ACTH and corticosterone (Suga et al. 2011). From a
translational perspective, ectopic placement in the subcutaneous tissue offers sig-
nificant advantages due to the low risk of the intervention (e.g., in a subcutaneous
location) and easy accessibility in case of complications. The experimental evalu-
ation of ectopic grafts may therefore be a justifiable strategy, though integration
within the hypothalamic-pituitary-target organ axis and homeostatic control is more
likely to be achieved if grafts are placed in the vicinity of the hypothalamus or even
within the gland itself. Interestingly, in humans, placement in the sella is simpler
than in rodents, due to the development of minimal invasive transnasal endoscopic
approaches to the sella and anterior skull base. Experimental evidence of hypo-
thalamic control upon grafting of pituitary cells requires complex assays and
readouts, including stimulation tests [e.g., response to thyrotropin releasing hor-
mone (TSH) or to growth hormone-releasing hormone (GHRH) etc.], physiological
stress tests [e.g., exposure to cold, arginine testing followed by evaluation of
variations in pituitary hormone levels (Akalan et al. 1988; Fisker et al. 1999;
Guillemin 2005)]. Behavioral testing can also contribute to the evaluation of the
integrity of the hypothalamic-pituitary-target organ axis and its feedback loops.
Demonstrating appropriate integration into the neuroendocrine system and its
physiological and homeostatic feedback loops should be considered an important
component of both efficacy and safety of this strategy. Obviously uncontrolled or
random secretion of key hormones such as ACTH or growth hormone can have
serious negative health consequences.
Additional considerations in translational strategies would include the possibil-
ity of grafting specific pituitary sublineages, e.g., ACTH- or growth hormone-
secreting. This approach might require more sophisticated differentiation protocols
and, likely, selection strategies that should be compatible with good manufacturing
practice (GMP) conditions and safety standards.
Conclusion
The recent successful derivation of pituitary placode lineage and the range of
anterior pituitary hormone-producing cells are very exciting advances that will
likely herald the development of restorative strategies in humans. Several chal-
lenges along the road to translation remain to be tackled. Key questions include the
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ability to develop selective pituitary sublineages that produce a single target
hormone, the development of grafting strategies for human patients, and the
demonstration of integration of the grafted cells into the hypothalamic-pituitary-
peripheral target axis, a goal that is fundamental to the safety assessment of the cell
therapy-based approach to hypopituitarism.
Note Added in Proof
A recent manuscript from our team presents a fully defined and efficient protocol
for the derivation of anterior pituitary hormone producing cells from human pluri-
potent stem cells and demonstrates hormone release in a rat model of hypo-
pituitarism (Zimm et al. 2016).
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